LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
33.91
-0.74 (-2.14%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.

Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.

The company is headquartered in Del Mar, California.

LENZ Therapeutics, Inc.
LENZ Therapeutics logo
Country United States
Founded 2019
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
CEO Evert Schimmelpennink

Contact Details

Address:
445 Marine View Avenue, Suite 320
Del Mar, California 92014
United States
Phone (858) 925-7000
Website lenz-tx.com

Stock Details

Ticker Symbol LENZ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001815776
ISIN Number US52635N1037
Employer ID 84-4867570
SIC Code 2836

Key Executives

Name Position
Evert B. Schimmelpennink President, Chief Executive Officer, Secretary and Director
Shawn Olsson Chief Commercial Officer
Marc G. Odrich M.D. Chief Medical Officer
James W. McCollum Co-Founder and Director
Daniel R. Chevallard CPA Chief Financial Officer
Domenick Porfidia Vice President of Sales
David Murphy Vice President of Marketing
Breianna Bowen Vice President of Human Resources
Marvin J. Garrett Senior Vice President of Regulatory and Quality

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 6, 2024 424B3 Prospectus
Nov 6, 2024 424B3 Prospectus
Nov 6, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Oct 28, 2024 424B3 Prospectus
Oct 28, 2024 424B3 Prospectus
Oct 28, 2024 8-K Current Report
Sep 19, 2024 EFFECT Notice of Effectiveness